An AMNOG dossier is not simply a collection of regulatory documents. It must translate the clinical development programme into the specific population, comparator, endpoint, analysis and cost requirements of the German benefit assessment process. The legal requirements are set out in the AMNOG framework, while the JCA-to-AMNOG guide explains which European evidence can be reused.
Last regulatory review: August 2026. Dynamic deadlines, thresholds and dossier requirements should be verified against current primary sources for each live procedure.
AMNOG dossier modules at a glance
The five modules have different functions. Modules 3 and 4 form the core of the German evidence and added-benefit assessment.
| Purpose | Primary content | Output |
|---|---|---|
| Module 1 | Administrative information and summary | Structured overview of the submission |
| Module 2 | Medicine, indication and treatment context | Definition of the assessed product and use |
| Module 3 | Comparator, target population, epidemiology and costs | German assessment and resource context |
| Module 4 | Clinical evidence, analyses and added benefit | Evidence for the G-BA benefit decision |
| Module 5 | References and supporting documents | Traceable source documentation |
The AMNOG dossier at a glance
What is an AMNOG dossier?
An AMNOG dossier is the pharmaceutical company’s formal evidence submission for the German early benefit assessment under Section 35a SGB V.
How many modules does an AMNOG dossier contain?
An AMNOG dossier contains five modules. Modules 1 to 4 contain the structured public submission. Module 5 contains the supporting study documents, references and source material.
Which module contains the added-benefit evidence?
Module 4 contains the methods, analyses and results used to demonstrate added benefit.
Which module contains epidemiology and costs?
Module 3 contains the disease description, German target population, epidemiology, treatment costs and requirements for quality-assured use.
Are all AMNOG dossier modules published?
Modules 1 to 4 are published on the G-BA website. Module 5 contains supporting documentation and is not published in the same form.
What is an AMNOG dossier?
The AMNOG dossier presents the evidence required to assess whether a medicine provides patient-relevant added benefit over the German appropriate comparator therapy.
The dossier connects several evidence domains:
- the authorised indication,
- the German treatment standard,
- the relevant patient population,
- epidemiological estimates,
- clinical study results,
- statistical analyses,
- treatment costs,
- and requirements for appropriate use.
The German dossier therefore performs a different function from a regulatory submission. A regulatory dossier supports marketing authorisation by demonstrating quality, efficacy and safety. The AMNOG dossier supports a comparative national assessment against the treatment standard defined by the G-BA.
Why is the AMNOG dossier called a benefit dossier?
The German term Nutzendossier can be translated as benefit dossier. In practice, however, the submission primarily addresses added benefit rather than benefit in isolation.
The central question is not whether the medicine has a therapeutic effect. The question is whether it offers an additional patient-relevant advantage compared with the appropriate comparator therapy.
Who submits the AMNOG dossier?
The pharmaceutical company responsible for placing the medicine on the German market submits the dossier to the G-BA.
The submission must be aligned with:
- the authorised wording of the indication,
- the relevant submission date,
- the current G-BA dossier templates,
- and the evidence available at the start of the procedure.
When must an AMNOG dossier be submitted?
For a medicine with a new active substance, the AMNOG dossier is generally submitted at the time of market entry in Germany.
The source materials identify market launch as the standard submission point for a new active substance. A dossier may also become necessary for a new authorised indication or another reassessment trigger.
The exact legal deadline and the applicable templates must be checked for the specific procedure. This is particularly relevant for indication extensions, orphan-drug reassessments and procedures linked to European Joint Clinical Assessments.
Why does preparation begin before submission?
The AMNOG dossier may be submitted at launch, but its preparation begins much earlier.
A complete dossier requires:
- validated clinical datasets,
- final statistical outputs,
- systematic literature searches,
- epidemiological analyses,
- German cost calculations,
- quality control,
- and consistent narratives across modules.
The dossier cannot be produced reliably between marketing authorisation and launch without substantial preparatory work.
What are the five modules of an AMNOG dossier?
The five AMNOG dossier modules separate administrative, clinical, epidemiological, economic and documentary content.
| Module | Main content |
|---|---|
| Module 1 | Administrative information and summary |
| Module 2 | Medicine, mechanism of action and authorised indication |
| Module 3 | Comparator, disease, target population, epidemiology and costs |
| Module 4 | Clinical evidence, methods, analyses and added benefit |
| Module 5 | Supporting study documentation and references |
The modular structure is not merely editorial. Each module answers a different part of the German assessment question. The supplied dossier material describes Modules 1 to 4 as the published core of the submission, supported by documents and references in Module 5.
Module 1 of the AMNOG dossier: administrative information and summary
Module 1 summarises the company’s position and the evidence presented in Modules 2 to 4.
It contains administrative information and a structured overview of:
- the medicine,
- the authorised indication,
- the relevant patient groups,
- the claimed added benefit,
- the magnitude and certainty of the claim,
- the target population,
- and treatment costs.
Module 1 is therefore more than a cover document. It provides the first consolidated representation of the company’s assessment position.
Why consistency in Module 1 matters
Every claim in Module 1 must be supported by the detailed evidence in the other modules.
Inconsistencies may arise when:
- patient populations differ between modules,
- the claimed added benefit is not aligned with the statistical results,
- cost estimates use different population assumptions,
- or the comparator description changes between the summary and the detailed evidence.
Module 1 should be finalised after the key conclusions in Modules 3 and 4 are stable.
Module 2 of the AMNOG dossier: medicine and authorised indication
Module 2 provides general information about the medicine, its mechanism of action and the authorised indication.
The source material assigns Module 2 to:
- administrative product information,
- the mechanism of action,
- and the authorised therapeutic indications.
Module 2 establishes the product context for the later modules.
Why the authorised indication matters
The exact wording of the authorised indication determines the scope of the national benefit assessment.
It influences:
- eligible patients,
- relevant subpopulations,
- treatment lines,
- biomarker definitions,
- comparator selection,
- and the applicability of clinical studies.
A small difference between the anticipated and final indication can affect whether a study population fully corresponds to the assessed population.
Module 3 of the AMNOG dossier: comparator, population, epidemiology and costs
Module 3 describes the German treatment and reimbursement context in which the medicine will be assessed.
According to the supplied dossier material, Module 3 covers:
- determination of the appropriate comparator therapy,
- description of the disease and target population,
- therapeutic need,
- prevalence and incidence in Germany,
- the number of patients in the target population,
- treatment costs for statutory health insurance,
- requirements for quality-assured use,
- and information on trial participants within the scope of the SGB V.
Module 3 is therefore the main national-context module.
Appropriate comparator therapy in Module 3
The appropriate comparator therapy, known in German as the zweckmäßige Vergleichstherapie or zVT, is the standard against which the added benefit is assessed.
Module 3 must explain:
- which comparator or comparators are relevant,
- which patient population each comparator applies to,
- how the comparator relates to German treatment practice,
- and how treatment costs are calculated.
The clinical implementation of the comparator is addressed in Module 4, but the German treatment context is established in Module 3.
Disease description and therapeutic need
The disease section should explain the condition in a way that supports the later assessment.
It should cover:
- disease course,
- clinically relevant manifestations,
- treatment objectives,
- existing treatment options,
- remaining therapeutic need,
- and the position of the new medicine in the treatment pathway.
Therapeutic need should not be used as a substitute for comparative evidence. It provides context but does not independently establish added benefit.
German target population
The target population in Module 3 estimates the number of patients within German statutory health insurance who are eligible for the medicine.
The derivation may require several steps:
- estimating the number of patients with the disease,
- applying indication-specific restrictions,
- applying treatment-line or biomarker criteria,
- accounting for diagnosis and treatment rates,
- and estimating the proportion covered by statutory health insurance.
Each step should be transparent and reproducible.
Epidemiology in Module 3
The epidemiological section commonly includes:
- prevalence,
- incidence,
- disease-specific subpopulations,
- demographic characteristics,
- and expected development of the patient population.
Relevant sources can include:
- official statistics,
- disease registries,
- claims data,
- published studies,
- and structured expert input.
Uncertainty should be shown explicitly rather than hidden in a single point estimate.
Treatment costs in Module 3
Module 3 calculates annual treatment costs for:
- the medicine under assessment,
- the appropriate comparator therapy,
- and relevant additional healthcare services.
The calculation may depend on:
- dose,
- treatment frequency,
- treatment duration,
- patient weight or body surface area,
- pack size,
- wastage,
- and mandatory accompanying measures.
The objective is not to predict the final reimbursement amount. The section provides a transparent representation of treatment costs under the dossier assumptions.
Requirements for quality-assured use
Module 3 can also describe requirements for appropriate and quality-assured use.
These may include:
- diagnostic testing,
- monitoring,
- specialist treatment settings,
- qualification requirements,
- or other conditions associated with administration.
Module 4 of the AMNOG dossier: clinical evidence and added benefit
Module 4 contains the methodological and clinical evidence used to derive added benefit.
The supplied materials assign Module 4 to:
- description of methods and results,
- identification of patient groups with therapeutic added benefit,
- systematic information retrieval,
- and, optionally, a separate analysis appendix.
Module 4 is the central clinical evidence module.
What is included in the Module 4 evidence base?
Module 4 typically documents:
- the research question,
- eligibility criteria,
- systematic literature searches,
- study selection,
- trial characteristics,
- risk of bias,
- endpoint results,
- subgroup analyses,
- sensitivity analyses,
- and the derivation of added benefit.
The evidence must be structured according to the patient populations and comparators relevant to Germany.
Systematic information retrieval
The evidence base in Module 4 must be identified through a transparent and reproducible information-retrieval process.
This includes searches for:
- company-sponsored studies,
- published trials,
- registry entries,
- study reports,
- and potentially relevant evidence not identified through the company’s own development programme.
The objective is to establish a complete study pool rather than to present only favourable evidence.
Direct comparative evidence
A randomised direct comparison against the appropriate comparator therapy usually provides the clearest basis for an added-benefit assessment.
The dossier must show that:
- the comparator was implemented appropriately,
- patients received treatment consistent with the relevant care context,
- endpoints are patient-relevant,
- and analyses correspond to the German assessment question.
Indirect comparative evidence
Where a direct comparison is unavailable, an adjusted indirect comparison may be considered.
The dossier must then justify:
- the comparison network,
- similarity between studies,
- consistency of endpoint definitions,
- availability of relevant effect modifiers,
- and the statistical method.
The presence of an indirect comparison does not itself establish evaluable evidence. Its assumptions and source data must be sufficiently transparent.
Patient-relevant endpoints in Module 4
The AMNOG assessment focuses on patient-relevant outcomes in:
- mortality,
- morbidity,
- health-related quality of life,
- and adverse events.
A regulatory endpoint is not automatically sufficient for Module 4. The dossier must justify its patient relevance, validity and operationalisation.
Subgroups and population-specific evidence
Module 4 must address the patient groups relevant to the assessment.
Subgroup analyses can be important where:
- the indication contains distinct treatment populations,
- the G-BA defines several comparators,
- the effect differs across clinically relevant characteristics,
- or only part of the authorised population is represented in the trial.
The dossier should distinguish prespecified, adequately powered population analyses from exploratory subgroup findings.
Deriving the magnitude and certainty of added benefit
The company derives an added-benefit claim from the totality of the evidence.
Possible magnitude categories include:
- major,
- considerable,
- minor,
- non-quantifiable,
- no added benefit proven,
- and less benefit.
The company must also address the certainty of the evidence.
The source material shows that company claims and subsequent assessments frequently differ. This underlines that the claim is the starting position of the procedure, not its final outcome.
Module 5 of the AMNOG dossier: supporting documents and references
Module 5 contains the documents used to substantiate the public dossier.
These may include:
- clinical study reports,
- statistical analysis documentation,
- study protocols,
- publications,
- search documentation,
- epidemiological references,
- and further source material.
Module 5 enables the assessing body to verify the claims and analyses presented in Modules 1 to 4.
Why document traceability matters
Each relevant statement in the public dossier should be traceable to an identifiable source.
Weak traceability can arise through:
- inconsistent study names,
- unclear table references,
- missing appendices,
- outdated reports,
- or analyses that cannot be reconstructed from the submitted documentation.
Document management is therefore a substantive part of dossier quality.
Why is a regulatory submission not enough for an AMNOG dossier?
A regulatory submission does not necessarily answer the German comparative assessment question.
Regulatory and AMNOG submissions differ in several respects:
| Regulatory submission | AMNOG dossier |
|---|---|
| Supports marketing authorisation | Supports German added-benefit assessment |
| Assesses efficacy, safety and quality | Assesses added benefit over the German comparator |
| Uses the regulatory trial population | Uses the authorised and AMNOG-relevant population |
| May accept surrogate outcomes | Prioritises patient-relevant outcomes |
| May use a globally accepted comparator | Requires alignment with the German zVT |
| Focuses on benefit-risk | Focuses on comparative benefit |
The same study can therefore be central to marketing authorisation but only partially suitable for the German benefit assessment.
Which evidence gaps commonly affect an AMNOG dossier?
The most consequential AMNOG dossier gaps usually concern comparator alignment, population coverage, endpoints and analytical availability.
The trial comparator does not match the German comparator
A study may compare the new medicine with placebo or an internationally accepted therapy while Germany requires another comparator.
This can limit direct evidence for the German assessment.
The study population does not cover the full authorised indication
The clinical study may exclude patients who later fall within the authorised indication.
The dossier must then clarify:
- which population is represented,
- whether evidence is transferable,
- and where no comparative evidence is available.
Relevant patient outcomes were not measured
An endpoint programme can be sufficient for authorisation yet incomplete for AMNOG.
Missing quality-of-life data or limited symptom assessment cannot always be remedied through post hoc analysis.
Required analyses are not available
Additional analyses may be required for:
- subgroups,
- responder thresholds,
- missing data,
- adverse events,
- or specific time points.
These analyses require early planning, dataset availability and sufficient validation time.
Epidemiology is not reproducible
Target-population estimates can become vulnerable when key assumptions are unsupported or data sources are inconsistent.
A robust Module 3 should show both the calculation and the uncertainty around it.
What special AMNOG dossier rules apply to orphan medicines?
Orphan medicines follow a simplified dossier approach while they remain within the applicable special statutory conditions.
The supplied materials state that, in the simplified setting:
- sections on the appropriate comparator therapy are not completed,
- a comparative added-benefit demonstration is not required in the regular form,
- and Module 4 focuses on the magnitude of added benefit based on the authorisation and the studies supporting it.
The materials refer to an annual turnover threshold of €30 million. Once that threshold is exceeded, a regular comparative assessment becomes relevant.
Because orphan-drug rules are legally dynamic, current requirements should be checked for each live procedure.
How does EU HTA affect the AMNOG dossier?
EU HTA changes how clinical evidence can be referenced and reused, but it does not remove the national AMNOG dossier structure.
The European dossier and the Joint Clinical Assessment may provide substantial parts of the clinical evidence base. Germany nevertheless retains national requirements relating to:
- the appropriate comparator therapy,
- national patient populations,
- epidemiology,
- treatment costs,
- quality-assured use,
- evidence updates,
- and the national added-benefit decision.
The existing AMNOG modules remain the national submission framework. References to European content may be possible, but they must be specific and must support the German assessment question.
What should manufacturers prepare before writing the AMNOG dossier?
The central AMNOG dossier decisions should be made before drafting begins.
A structured readiness assessment should cover:
- the final or anticipated indication,
- the German comparator and population structure,
- the eligible study pool,
- endpoint acceptance,
- required statistical analyses,
- literature-search timing,
- epidemiological sources,
- cost assumptions,
- document availability,
- and dependencies on the JCA process.
The dossier-writing phase should integrate these decisions. It should not be the first stage at which they are discussed.
The AMNOG dossier is a national evidence translation
The AMNOG dossier translates clinical evidence into the population, comparator, endpoint and reimbursement context of the German benefit assessment.
Its five modules divide that task into a clear structure:
- Module 1 summarises the submission.
- Module 2 defines the medicine and indication.
- Module 3 establishes the German treatment, population and cost context.
- Module 4 presents the clinical evidence and added-benefit claim.
- Module 5 provides the supporting documentation.
Under EU HTA, this national translation remains necessary. The European evidence package may become an important source, but the German dossier must still show whether that evidence is sufficient for the specific AMNOG question.
Frequently asked questions about the AMNOG dossier
What is an AMNOG dossier?
An AMNOG dossier is the structured submission used to support the German early benefit assessment of a new medicine.
How many modules are in an AMNOG dossier?
The AMNOG dossier contains five modules.
What is in Module 3 of the AMNOG dossier?
Module 3 contains the appropriate comparator therapy, disease and target population, German epidemiology, treatment costs and requirements for quality-assured use.
What is in Module 4 of the AMNOG dossier?
Module 4 contains the clinical methods, systematic evidence searches, study results, statistical analyses and derivation of added benefit.
Are AMNOG dossier modules public?
Modules 1 to 4 are published by the G-BA. Module 5 contains supporting documentation and is not published in the same form.
Is an AMNOG dossier the same as a value dossier?
The terms overlap, but the AMNOG dossier is the formally structured German submission governed by specific national templates and assessment requirements.
Is the clinical study report sufficient for an AMNOG dossier?
No. Additional searches, analyses, population mappings, epidemiology and cost information are usually required.
Does an orphan medicine require an AMNOG dossier?
Yes. Orphan medicines require an AMNOG submission, although simplified rules may apply while the medicine remains within the relevant statutory conditions.
Does the JCA replace the AMNOG dossier?
No. The JCA does not replace the national AMNOG dossier or the German added-benefit decision.